FR2849381A1 - Cosmetic or dermatological skin-treatment composition, useful e.g. for sun-tanning, comprises a complex of an endonuclease with a nucleotide or nucleic acid - Google Patents

Cosmetic or dermatological skin-treatment composition, useful e.g. for sun-tanning, comprises a complex of an endonuclease with a nucleotide or nucleic acid Download PDF

Info

Publication number
FR2849381A1
FR2849381A1 FR0216872A FR0216872A FR2849381A1 FR 2849381 A1 FR2849381 A1 FR 2849381A1 FR 0216872 A FR0216872 A FR 0216872A FR 0216872 A FR0216872 A FR 0216872A FR 2849381 A1 FR2849381 A1 FR 2849381A1
Authority
FR
France
Prior art keywords
cosmetic
skin
nucleotide
composition
endonuclease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0216872A
Other languages
French (fr)
Other versions
FR2849381B1 (en
Inventor
Jean Noel Thorel
Cerard Redziniak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thorel Jean Noel
Original Assignee
Thorel Jean Noel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thorel Jean Noel filed Critical Thorel Jean Noel
Priority to FR0216872A priority Critical patent/FR2849381B1/en
Priority claimed from US10/537,816 external-priority patent/US20060029563A1/en
Publication of FR2849381A1 publication Critical patent/FR2849381A1/en
Application granted granted Critical
Publication of FR2849381B1 publication Critical patent/FR2849381B1/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/004Aftersun preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/606Nucleosides; Nucleotides; Nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/04Preparations for care of the skin for chemically tanning the skin

Abstract

A cosmetic and/or dermo-cosmetic composition (A) comprises an active complex (I), between a peptide and/or protein, i.e. an endonuclease (Ia) and a (poly)nucleotide and/or nucleic acid (Ib). Cosmetic and/or dermo-cosmetic composition (A) contains an active complex (I) between at least one peptide and/or protein, i.e. an endonuclease (Ia) and at least one (poly)nucleotide and/or nucleic acid (Ib). (Ib) is adenosine (A), guanosine (G), cytosine (C), uridine (U) or thymidine (T) monophosphates; deoxy forms of T, A, C or G monophosphates; A, G, U or T triphosphates; guanosine tetraphosphate; IP3; hydrolyzates of DNA and/or RNA; UDP-glucose-galactose or UDP-N-acetyl glucosamine; G diphosphate-mannose, or C monophosphate-N-acetylneuraminic acid.

Description

<Desc/Clms Page number 1> <Desc / CRUD Page number 1>

COMPOSITION COSMETIQUE, SOLAIRE ET BIO-BRONZANTE COSMETIC, AND BIO-SOLAR TANNING
La présente invention concerne les compositions à usage topique, destinées au traitement superficiel ou systémique des parties superficielles du corps humain ou animal, par exemple de la peau. The present invention relates to compositions for topical use, intended for the superficial or systemic treatment of superficial parts of the human or animal body, for example the skin.

La peau constitue l'enveloppe de revêtement du corps, le protégeant des agressions extérieures. The skin is the body of the coating enclosure, protecting it from external aggressions. Outre ses caractéristiques physiques, la peau est composée de différents composés chimiques, parmi lesquels : - l'eau qui constitue environ 70% de la composition de la peau, sa répartition varie selon les différentes couches cutanées, l'hypoderme étant le plus hydraté ; In addition to its physical characteristics, the skin is composed of different chemical compounds, such as: - water constitutes about 70% of the composition of the skin, its distribution varies in different skin layers, the hypodermis is the more hydrated; - des sels minéraux parmi lesquels on distingue les sels de métaux et les sels de métalloïdes ; - minerals among which are the metal salts and metalloid salts; - des protides comprenant des acides aminés comme la tyrosine, la cystine, l'hydroxyproline , la valine, et des protéines comme les collagènes, l'élastine, la kératine, mais également des enzymes, et des hormones ; - of proteins comprising amino acids such as tyrosine, cystine, hydroxyproline, valine, and proteins such as collagens, elastin, keratin, but also enzymes, and hormones; - des acides nucléiques, à savoir ADN et/ou ARN ; - nucleic acids, namely DNA and / or RNA; - des lipides regroupant les sphingolipides, le cholestérol, les acides gras, les triglycérides et les prostaglandines ; - Lipid grouping sphingolipids, cholesterol, fatty acids, triglycerides and prostaglandins; - des glucides, etc ; - carbohydrates, etc;
La plupart de ces substances ou composés, ainsi que beaucoup d'autres plus complexes forment le film cutané de surface, ou film hydrolipidique, défini comme une émulsion de type eau dans huile recouvrant la couche cornée. Most of these substances or compounds, as well as many other more complex form the skin film surface or hydrolipidic film, defined as a water-in-oil emulsion layer covering the cornea.

Le rôle de ce film consiste à maintenir l'hydratation de la couche cornée, maintenir l'acidité cutanée, et jouer un rôle de barrière contre les agressions extérieures et les agents pathogènes. The role of this film is to maintain the hydration of the stratum corneum, maintain skin acidity and act as a barrier against external aggression and pathogens.

En surface, la peau est constituée de l'épiderme qui est un tissu épithélial stratifié, c'est-à-dire un ensemble de cellules semblables entre elles réunies pour accomplir une même fonction ; On the surface, the skin consists of epidermis is a stratified epithelial tissue, that is to say a collection of similar cells combined together to accomplish the same function; en couche intermédiaire elle est constituée du derme, tissu conjonctif, et en couche profonde de l'hypoderme, tissu conjonctif adipeux. intermediate layer is comprised of dermis, connective tissue, and deep layer of the hypodermis, adipose connective tissue.

L'épiderme est un épithélium de revêtement cutané dont la fonction majeure est de protéger ; The epidermis is an epithelium of skin covering whose major function is to protect; il est constitué de quatre types de cellules, les cellules de Langerhans, les cellules de Merckel, les mélanocytes, les kératinocytes. it is constituted of four types of cells, Langerhans cells, Merkel cells, melanocytes, keratinocytes.

<Desc/Clms Page number 2> <Desc / CRUD Page number 2>

Les kératinocytes, cellules épidermiques les plus nombreuses jouent un rôle essentiel dans le phénomène de kératinisation de l'épiderme, elles sont réparties sur six couches dont les trois les plus proches de la surface de la peau sont, le stratum lucidum, le stratum cornéum et le stratum disjunctum, qui forment l'enveloppe superficielle dans laquelle la majorité des produits cosmétiques et ou dermatologiques exercent leur activité. Keratinocytes, the most numerous epidermal cells play an essential role in the phenomenon of keratinization of the epidermis, they are spread over six layers, the three closest to the surface of the skin is the stratum lucidum, the stratum corneum and disjunctum the stratum which form the surface casing in which the majority of cosmetic and dermatological products or operate.

On attribue classiquement trois rôles à cette couche cornée, notamment un rôle métabolique, les deux autres rôles étant la régulation thermique et la protection des organes internes. conventionally assigned three roles in this stratum corneum, including a metabolic role, the other two roles being the thermal regulation and protection of internal organs.

L'épiderme comme tous les autres tissus possède l'ensemble des systèmes enzymatiques nécessaires au maintien des activités cellulaires, telles que par exemple, le métabolisme de base, la respiration et la division cellulaire. The skin like any other tissue has all the enzyme systems necessary for maintaining cellular activities, such as for example, the basic metabolism, respiration and cell division.

Ces systèmes enzymatiques participent à l'élaboration de la fonction principale, c'est-à-dire établir une barrière pour protéger la peau des atteintes de l'environnement et cette fonction est assurée en grande partie par le stratum cornéum. These enzyme systems involved in the development of the main function, that is to say establish a barrier to protect the skin from damage to the environment and this function is provided largely by the stratum corneum. L'épiderme doit aussi protéger l'organisme des rayonnements ultraviolets, et cette fonction est assurée par le système pigmentaire. The skin must also protect the body from ultraviolet radiation, and this function is provided by the pigment system.

Les enzymes sont des macromolécules protéiques, agissant comme des catalyseurs biochimiques, leurs principales propriétés étant d'accélérer les réactions du monde vivant La plupart des enzymes contenues dans la couche cornée catalyse des dégradations, ce sont principalement des hydrolases. Enzymes are protein macromolecules, acting as biochemical catalysts, their main properties is to accelerate the reactions of the living world Most enzymes in catalysis horny layer degradation, they are mainly hydrolases.

Mais si la peau constitue une barrière très efficace, elle peut cependant être traversée par de petites quantités de substances lipophiles, capables de pénétrer dans les couches cornées ; But if the skin is a highly effective barrier, however, it may be traversed by small amounts of lipophilic substances, able to penetrate the stratum corneum; en fonction de leur hydrophilie, ces substances pourront diffuser plus profondément et ainsi avoir une activité systémique. depending on their hydrophilic, these substances can diffuse more deeply and have a systemic activity.

Les mécanismes de la pénétration de principes actifs aux différents niveaux de la peau sont très complexes, ils dépendent cependant des propriétés physico-chimiques des principes actifs et des excipients utilisés dans les formulations, de l'état de la peau et du mode d'application. The mechanisms of penetration of active ingredients to the different levels of the skin are very complex, however, they depend on the physicochemical properties of the active ingredients and excipients used in the formulations of the skin condition and the mode of application .

La présente invention procède du concept inventif suivant. The present invention proceeds from the following inventive concept.

La réponse aux différents disfonctionnements de la peau se trouve dans la peau elle-même. The answer to various malfunctions of the skin is in the skin itself. La peau possède en elle-même toutes les réponses pour lutter contre les agressions extérieures, pour se renouveler, pour corriger les petites imperfections qui apparaissent. The skin itself has all the answers to fight against external aggression, to renew, to correct small imperfections that appear.

<Desc/Clms Page number 3> <Desc / CRUD Page number 3>

Mais, soit les agressions sont trop nombreuses, ou différentes au même moment, ou trop répétées, et les mécanismes naturels de défense ou réponse existant dans la peau ne peuvent plus suffire à corriger et à défendre celle-ci contre lesdites agressions, soit sous l'effet du vieillissement les mécanismes permettant par exemple la régénérescence ne sont plus suffisamment actifs pour permettre un renouvellement suffisant, moléculaire, cellulaire, ou tissulaire, pour garder à la peau un aspect satisfaisant. But whether the attacks are too numerous or different at the same time, or too repeated, and the natural defense mechanisms or existing response in the skin can no longer be enough to correct it and to defend it against such attacks, either in the effect of aging mechanisms for such regeneration is not active enough to allow sufficient renewal, molecular, cellular, and tissue, keeping the skin a satisfactory appearance.

C'est alors que différentes pathologies de la peau apparaissent. Then various diseases of the skin appear.

La présente invention a donc pour objet une nouvelle classe d'actifs conférant à la peau ou aux parties superficielles du corps humain ou animal, la capacité d'agir ou de réagir par elle-même à toute agression ou disfonctionnement, uniquement en activant des mécanismes moléculaires, et/ou cellulaires, et/ou tissulaires, par exemple métaboliques, préexistant dans la peau ou ladite partie superficielle du corps humain ou animal. The present invention thus provides a new asset class giving the skin or superficial parts of the human or animal body, the ability to act or react with itself to any aggression or malfunction, only by activating mechanisms molecular and / or cellular and / or tissue, for example, metabolic, pre-existing in the skin or said surface portion of the human or animal body.

Conformément à la présente invention, il est proposé, aux fins précitées, une composition à usage topique, par exemple cosmétique ou dermo-cosmétique, comprenant de manière nouvelle un complexe actif constitué d'au moins un peptide ou une protéine choisi dans le groupe constitué par les endonucléases, le peptide Met-Gln-Met-Lys-Lys-Val-Leu-AspSer, l'alpha MSH ("melanocyte stimulating hormon"), la mélanostanine, et la photolyase, et d'au moins un nucléotide, polynucléotide, ou acide nucléïque, choisi dans le groupe constitué par de l'AMP, GMP, CMP, UMP, dTMP, dAMP, dCMP, dGMP, ATP, GTP, CTP, UTP, TMP, GP4G, IP3, les hydrolysats d'ADN, et/ou ARN, l'UDP-glucose-galactose, le GDP-mannose, l'UDP-N-acétyl glusosamine, le CMP-N-acétyl acide neuramique. According to the present invention there is provided for these purposes, a topical composition, for example cosmetic or dermo-cosmetic comprising new manner an active complex consisting of at least one peptide or a protein selected from the group consisting endonuclease, the peptide Met-Gln-Met-Lys-Lys-Val-Leu-AspSer, alpha MSH ( "melanocyte stimulating hormon"), the mélanostanine and photolyase, and at least one nucleotide, polynucleotide or nucleic acid selected from the group consisting of AMP, GMP, CMP, UMP, dTMP, dAMP, dCMP, dGMP, ATP, GTP, CTP, UTP, TMP, GP4G, IP3, DNA hydrolysates, and / or RNA, UDP-glucose-galactose, GDP-mannose, UDP-N-acetyl glusosamine, CMP-N-acetyl neuraminic acid.

Le complexe actif selon l'invention permet à la peau de produire elle-même les éléments nécessaires dont elle a besoin pour assurer son équilibre, et fonctionner idéalement en donnant ou redonnant à la peau la capacité de s'adapter, de résister et de développer éventuellement une protection. The active complex according to the invention allows the skin to produce itself the necessary elements it needs for its balance, and ideally run giving or restoring the ability to adapt the skin to resist and develop optionally protected.

Le processus d'action d'un complexe actif selon l'invention est sans doute bio-enzymologique. The action process of an active complex of the invention is probably bio-enzymology. Il repose sur l'effet conjugué d'acides nucléiques et de protéines et/ou peptides. It is based on the combined effect of nucleic acids and proteins and / or peptides.

Acides nucléiques et protéines sont consubstantiels à la vie. nucleic acids and proteins are consubstantial to life.

Le processus mis en #uvre avec un complexe actif selon la présente invention se différencie radicalement des processus habituels de la The process in #uvre with an active complex according to the present invention is radically different from the usual process

<Desc/Clms Page number 4> <Desc / CRUD Page number 4>

cosmétologie, car il tient compte de l'ensemble des interactions du système cutané, agit sur l'intégralité de la cellule et de son environnement, et respecte l'ensemble des cellules de la peau. cosmetology, because it takes into account all the interactions of the cutaneous system, affects the entire cell and its environment, and respects all skin cells.

En réactivant les mécanismes des cellules de la peau, tout complexe actif selon l'invention réapprend à l'épiderme à utiliser ses propres ressources. By reactivating the mechanisms of skin cells, while active complex according to the invention learns to skin to use its own resources.

En réveillant la mémoire des cellules et en stimulant leurs potentiels, tout complexe actif selon l'invention permet à la peau de retrouver ses facultés originelles, et/ou de mettre en #uvre des facultés de défense et de lutte contre les agressions extérieures, qui n'étaient pas ou étaient insuffisamment stimulées. By awakening the memory cells and stimulating their potential, while active complex according to the invention allows the skin to regain its original faculties, and / or to #uvre faculties of defense and struggle against external aggression, which were not or were insufficiently stimulated.

L'art antérieur décrit, certes, l'utilisation de peptides ou d'oligonucléotides dans des applications cosmétiques. The prior art describes, certainly, the use of peptides or oligonucleotides in cosmetic applications. Le brevet FR 98 09193 décrit par exemple une application où des peptides sont rendus lipophiles par un greffage d'un acide gras, de plus ou moins longue chaîne, sur l'amine N-terminale, et/ou d'estérifier le groupe carboxyle du peptide. FR 98 09193 discloses such an application where the peptides are rendered lipophilic by grafting of a fatty acid, or long chain on the N-terminal amine, and / or esterifying the carboxyl group of the peptide. Les produits selon cette invention ne sont pas utilisables dans des formulations ou lotions constitués uniquement d'ingrédients aqueux. The products according to this invention can not be used in formulations or lotions being solely aqueous ingredients.

L'utilisation d'acides nucléiques, en particulier d'oligonucléotides, pour traiter des maladies est connue ; The use of nucleic acids, particularly oligonucleotides, to treat diseases is known; en particulier une application est décrite dans le brevet WO 99/25819. in particular an application is described in WO 99/25819. Les oligonucléotides décrits sont utilisés seuls, et ils sont utilisés comme antisens, c'est à dire qu'il bloquent des mécanismes biologiques. The described oligonucleotides are used alone, and they are used as antisense, ie that block the biological mechanisms.

Dans un complexe actif selon l'invention, un peptide est utilisé dans sa forme naturelle, ou en association avec un oligonucléotide, par exemple. In an active complex according to the invention, a peptide is used in its natural form or in combination with an oligonucleotide, for example.

L'effet synergique obtenu est tout à fait inattendu et fait l'objet de l'invention. The resultant synergistic effect is quite unexpected and is the subject of the invention.

Les peptides, entrant dans la constitution d'un complexe actif selon l'invention, peuvent être obtenus soit par synthèse chimique classique (en phase solide ou en phase homogène liquide), soit par synthèse enzymatique (Kullman et al., J. Biol. Chem. 1980, 255, 8234), à partir des acides aminés constitutifs ou de leurs dérivés. Peptides, used in the formation of an active complex according to the invention can be obtained either by conventional chemical synthesis (solid phase or in homogeneous liquid phase), or by enzymatic synthesis (Kullman et al., J. Biol. Chem. 1980, 255, 8234), from the constituent amino acids or their derivatives.

Les peptides peuvent être obtenus également par fermentation d'une souche de bactérie, modifiée ou non par génie génétique, pour produire les séquences recherchées ou leurs différents fragments. The peptides can also be obtained by fermentation of a strain of bacteria, modified or unmodified by genetic engineering, to produce the desired sequences or their various fragments.

Enfin, les peptides peuvent être obtenus par extraction de protéines d'origine animale ou végétale, préférentiellement végétale, suivie d'une Finally, the peptides may be obtained by extraction of proteins of animal or plant origin, preferably plant, followed by a

<Desc/Clms Page number 5> <Desc / CRUD Page number 5>

hydrolyse contrôlée qui libère les fragments peptidiques en question, De nombreuses protéines trouvées dans les plantes sont susceptibles de contenir des séquences intéressantes au sein de leur structure. controlled hydrolysis which liberates the peptide fragments in question, many proteins found in plants are likely to contain sequences of interest in their structure. L'hydrolyse ménagée permet de dégager ces fragments peptidiques. Controlled hydrolysis permits to release these peptide fragments.

Pour obtenir un peptide entrant dans la constitution d'un complexe actif selon l'invention, il est possible, mais non nécessaire, d'extraire soit les protéines concernées d'abord et de les hydrolyser ensuite, soit d'effectuer l'hydrolyse d'abord sur un extrait brut et de purifier les fragments peptidiques ensuite. To obtain a peptide used in the formation of an active complex according to the invention, it is possible, but not necessary, to extract either the proteins concerned initially and then to hydrolyze them, or to perform the hydrolysis of first on a crude extract and purify the peptide fragments. On peut également utiliser l'hydrolysât sans en extraire les fragments peptidiques en question, en s'assurant toutefois d'avoir arrêté la réaction enzymatique d'hydrolyse à temps et de doser la présence des peptides en question par des moyens analytiques appropriés (traçage par radioactivité, immunofluorescence, ou immunoprécipitation avec des anticorps spécifiques, etc.). One can also use the hydrolyzate without extracting the peptide fragments in question, however ensuring to have stopped the enzymatic reaction of hydrolysis time and assaying the presence of the peptides in question by suitable analytical means (tracing by radioactivity, immunofluorescence or immunoprecipitation with specific antibodies, etc.).

D'autres procédés, plus simples ou plus complexes, conduisant à des produits moins chers ou plus purs sont facilement envisageables par l'homme de l'art connaissant le métier de l'extraction et de la purification des protéines et peptides. Other processes, simpler or more complex, leading to cheaper and purer products are readily envisaged by the skilled person knowing the craft of extraction and purification of proteins and peptides.

Les extraits d'ADN ou ARN entrant dans la constitution d'un complexe actif selon l'invention sont obtenus par hydrolyse enzymatique contrôlée, à partir par exemple de toute source naturelle facilement disponible. The DNA or RNA extracts used in the formation of an active complex according to the invention are obtained by controlled enzymatic hydrolysis, from for example any natural source readily available.

Ils peuvent également être obtenus par synthèse en utilisant un synthétiseur automatique. They can also be obtained by synthesis using an automated synthesizer.

D'autres procédés, plus simples ou plus complexes, conduisant à des produits moins chers ou plus purs sont facilement envisageables par l'homme de l'art connaissant le métier de la synthèse ou de l'hydrolyse des oligonucléotides. Other methods, simpler or more complex, leading to cheaper or purer products are readily envisaged by those skilled in the art knowing the art of the synthesis or hydrolysis of oligonucleotides.

Les oligonucléotides ou nucléotides susceptibles d'entrer dans la constitution d'un complexe actif selon la présente invention seront choisis parmi les extraits d'ADN, les extraits d'ARN, les extraits biologiques comme les biolysats de microorganismes, les extraits végétaux, et les extraits de plancton riches en oligonucléptides, en fonction des peptides et/ou protéines et de leur capacité à stimuler leur action. The oligonucleotides or nucleotides capable of entering into the formation of an active complex according to the present invention will be selected from the DNA extracts, the RNA extracts, biological extracts such as biolysats microorganisms, plant extracts, and rich plankton extracts oligonucléptides, based on peptides and / or proteins and their ability to stimulate their action.

<Desc/Clms Page number 6> <Desc / CRUD Page number 6>

L'invention concerne donc une composition cosmétique et/ou dermocosmétique, caractérisée en ce qu'elle comprend un complexe actif associant, au moins un peptide et/ou une protéine avec au moins un nucléotide, et/ou polynucléotide, et/ou un acide nucléique. The invention therefore relates to a cosmetic and / or dermocosmetic, characterized in that it comprises an active complex associating at least one peptide and / or a protein with at least one nucleotide, and / or polynucleotide, and / or an acid nucleic.

De préférence, les composants du complexe actif agissent ensemble de manière synergique. Preferably, the components of the active complex act together in a synergistic manner.

Dans un mode de réalisation, les peptides et/ou protéines représentent entre 1/10 à 8% et 0,1% en poids de la composition, et les nucléotides, polynucléotides et acides nucléiques représentent entre 2/10 à 8% et 0,2% en poids de ladite composition, ou entre 0,1% et 20% en poids de la composition, lorsque les nucléotides sont des extraits ou hydrosats d'ADN ou d'ARN. In one embodiment, the peptides and / or proteins are from 1/10 to 8% and 0.1% by weight of the composition, and nucleotides, polynucleotides and nucleic acids are between 2/10 to 8% and 0, 2% by weight of said composition, or between 0.1% and 20% by weight of the composition, when nucleotides are extracts or DNA or RNA hydrosats.

Selon l'invention, les peptides et/ou protéines sont mis en oeuvre, seuls ou en association entre eux, dans un produit cosmétique ou dermopharmaceutique fini, sous forme de solution, de dispersion, d'émulsion, ou encapsulées dans des vecteurs comme les macro-, micro- ou nanocapsules, des liposomes ou des chylomicrons, ou inclus dans des macro-, micro-ou nanoparticules, ou dans des microéponges, ou adsorbés sur des polymères organiques poudreux, les talcs, bentonites et autres supports minéraux. According to the invention, peptides and / or proteins are used, alone or in combination with each other, in a cosmetic or dermopharmaceutical finished product in the form of solution, dispersion, emulsion, or encapsulated in vectors such as macro-, micro- or nanocapsules, liposomes or chylomicrons, or included in macro-, micro- or nanoparticles or in microsponges, or adsorbed on powdery organic polymers, talcs, bentonites and other mineral supports.

Les produits cosmétiques ou dermopharmaceutiques finis, seront formulés selon toute forme galénique: comme les émulsions H/E et E/H, laits, lotions, polymères gélifiants et viscosants, tensioactifs et émulsifiants, pommades, lotions capillaires, shampooings, savons, poudres, sticks et crayons, sprays, huiles corporelles. The cosmetic or dermopharmaceutical finished, will be formulated according to any galenic form: such as O / W emulsions and W / O, milks, lotions, gelling polymers and viscosifiers, surfactants and emulsifiers, ointments, hair lotions, shampoos, soaps, powders, sticks and pencils, sprays, body oils.

Les ingrédients habituellement utilisés comme les lipides d'extraction et ou de synthèse, polymères gélifiants et viscosants, tensioactifs et émulsifiants, principes actifs hydro- ou liposolubles, extraits de plantes, extraits tissulaires, extraits marins, et autres agents biologiques seront additionnés aux formulations selon les règles habituellement utilisées. The ingredients typically used as the extraction and lipids or synthetic polymer gelling and thickening, surfactants and emulsifiers, active hydro or fat, plant extracts, tissue extracts, marine extracts, and other biological agents will be added to formulations rules customarily used.

A titre d'exemple, un complexe actif selon l'invention peut entrer dans la composition d'un lait solaire bio-bronzant, comprenant par ailleurs tous ingrédients et excipients entrant classiquement dans la composition d'un lait. For example, an active complex according to the invention can enter into the composition of a sunscreen lotion bio-tanning, further comprising all ingredients and excipients conventionally used in the composition of milk.

A titre d'exemples illustrant l'invention, on cite ci-après quelques formules cosmétiques représentatives, mais non limitatives de l'invention. Examples illustrating the invention, below lists some representative cosmetic formulations, but not limiting of the invention.

<Desc/Clms Page number 7> <Desc / CRUD Page number 7>

Exemple n 1 : Gel Bronzant après soleil Example 1: Tanning Gel after sun
Carbopol 1342R 0,3% (en poids) Carbopol 1342R 0.3% (by weight)
Butylène glycol 2,0% Butylene glycol 2.0%
Cylomethicone 6,0% Cylomethicone 6.0%
Alcool cétylique 0,5% Cetyl alcohol 0.5%
Glycérine 10% Glycerin 10%
TEA 0,3% TEA 0.3%
MSH (peptide) 0,01% MSH (peptide) 0.01%
DNA 1.00% DNA 1.00%
GP4G (Guanosine tétraphosphate) 1.00% GP4G (guanosine tetraphosphate) 1.00%
Eau, conservateurs, parfum qsp 100% Exemple 2 : Crème solaire bronzante et protectrice Water, preservatives, fragrance qs 100% Example 2: Sunscreen and protective tanning
Butyl-méthoxydibenzoylméthane 3,00 % (en poids) Butyl methoxydibenzoylmethane 3.00% (by weight)
Octyl-triazone 2,00 % Octyl triazone 2.00%
Alcool cétylique 0,50 % Cetyl alcohol 0.50%
Diméthicone 0,50 % Dimethicone 0.50%
Benzoate de C12 C15 6,00% Benzoate C12 C15 6.00%
Dioxyde de titane (MT 100Z) 3,00 % titanium dioxide (MT 100Z) 3.00%
PVP/Copolymère Eicosène 2,00 % PVP / Eicosene Copolymer 2.00%
Cétyl-phosphate de potassium 2,00 % potassium cetyl phosphate 2.00%
Méthyl et propyl-paraben 0,25 % Methyl and propyl paraben 0.25%
Disodium EDTA 0,10 % Disodium EDTA 0.10%
BHT 0,05 % BHT 0.05%
Carbomer 10,00 % Carbomer 10.00%
MSH 0,00002 % MSH 0.00002%
ATP 0,00005 % ATP 0.00005%
Peptide Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser 0,000001 % Peptide Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser 0.000001%
Hydroxyde de potassium 4,05 % potassium hydroxide 4.05%
Acide phénylbenzimidazole sulfonique 2,00 % phenylbenzimidazole sulfonic acid 2.00%
Acétate de tocophéryle 2,50 % Tocopheryl acetate 2.50%
Panthénol 1,00 % Panthenol 1.00%
Parfum qs. Fragrance qs.

Eau qsp. Water ad. 100 % 100%

<Desc/Clms Page number 8> <Desc / CRUD Page number 8>

Exemple 3 : crème solaire anti-inflammatoire Example 3: Anti-inflammatory sunscreen
Benzoate de C12 C15 3,00 % (en poids) Benzoate C12 C15 3.00% (by weight)
Stéarate d'octyle 3,00 % Octyl stearate 3.00%
Isoamyl-p-méthoxycinnamate 5,00 % Isoamyl p-methoxycinnamate 5.00%
Butyl-méthoxydibenzoylméthane 1,00 % Butyl methoxydibenzoylmethane 1.00%
Diisostéarate de polyglycéryl-3 4,00 % Polyglyceryl-3 diisostearate 4.00%
PEG-20 Laurate de glycéryle 1,00 % PEG-20 glyceryl laurate 1.00%
Carbomer 0,4 % Carbomer 0.4%
Propylène glycol 2,00 % Propylene glycol 2.00%
Conservateurs 0,50 % Preservatives 0.50%
Gomme de xanthane 0,30 % Xanthan gum 0.30%
Triéthanolamine 0,85 % Triethanolamine 0.85%
Acide phénylbenzimidazole-sulfonique 2,5 % phenylbenzimidazole sulfonic acid 2.5%
Acétyl-tyrosine 2,00 % Acetyl Tyrosine 2.00%
Peptide Met-Gln-Met-Lys-Lys Val-Leu-Asp-Ser 0,000001 % Peptide Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser 0.000001%
UDP-Glucose-galactose, 2/10-6 % UDP-Glucose-galactose, 2 / 10-6%
Eau qsp.100% Water qsp.100%
Parfum qs. Fragrance qs.

Exemple 4 : Crème solaire. Example 4: Sunscreen.

Ethoxy-diglycol 8,00 % (en poids) Ethoxy diglycol 8.00% (by weight)
Octyle salicylate 5,00 % Octyl salicylate 5.00%
Méthoxycinnamate d'octyle 7,50 % Octyl methoxycinnamate 7.50%
Butyl-méthoxydibenzoylméthane 2,00 % Butyl methoxydibenzoylmethane 2.00%
Diméthicone triméthylsiloxysilicate 3,00 % Trimethyl dimethicone 3.00%
Acétate de tocophéryle 0,20 % Tocopheryl acetate 0.20%
Distéarate de sucrose 5,00 % sucrose distearate 5.00%
Glycérine 5,00 % Glycerin 5.00%
Photolyase Photosome 0,50 % Photolyase photosome 0.50%
ADN de saumon 1,00 % Salmon DNA 1.00%
Butyl-, Méthyl-, Propyl-paraben + Phénoxyéthanol 0,40 % Butyl, Methyl, Propyl paraben + 0.40% Phenoxyethanol
Eau qsp.100 % Water qsp.100%
Parfum qs. Fragrance qs.

Claims (3)

REVENDICATIONS
1. Composition cosmétique et/ou dermocosmétique, caractérisée en ce qu'elle comprend un complexe actif constitué d'au moins un peptide ou une protéine choisi dans le groupe constitué par les endonucléases, et d'au moins un nucléotide, polynucléotide, ou acide nucléique choisi dans le groupe constitué par l'AMP, GMP, CMP, UMP, dTMP, dAMP, dCMP, dGMP, ATP, GTP, CTP, UTP, TMP, GP4G, IP3, les hydrolysats d'ADN, et/ou ARN, l'UDPglucose-galactose, le GDP-mannose, l'UDP-N-acétyl glusosamine, le CMP-Nacétyl acide neuramique. 1. Cosmetic and / or dermocosmetic, characterized in that it comprises an active complex consisting of at least one peptide or a protein selected from the group consisting of endonucleases and at least one nucleotide, polynucleotide, or acid nucleic selected from the group consisting of AMP, GMP, CMP, UMP, dTMP, dAMP, dCMP, dGMP, ATP, GTP, CTP, UTP, TMP, GP4G, IP3, DNA hydrolysates, and / or RNA, the UDPglucose-galactose, GDP-mannose, UDP-Nacétyl glusosamine, CMP-neuraminic acid Nacétyl.
2. Composition selon la revendication 1, caractérisée en ce que les peptides et/ou protéines représentent entre 1/10 à 8% et 0,1% en poids de la composition, ou entre 0,1% et 20% en poids de la composition, lorsque les nucléotides sont des extraits ou hydrolysats de l'ADN, et/ou ARN. 2. Composition according to claim 1, characterized in that the peptides and / or proteins are from 1/10 to 8% and 0.1% by weight of the composition, or between 0.1% and 20% by weight of the composition, when nucleotides are extracts or hydrolysates of DNA and / or RNA.
3. Composition selon la revendication 1, caractérisée en ce que les nucléotides représentent entre 2/10 à 8% et 0,2% en poids de la composition. 3. Composition according to claim 1, characterized in that nucleotides represent between 2/10 to 8% and 0.2% by weight of the composition.
FR0216872A 2002-12-30 2002-12-30 Cosmetic composition, solar and bio-tanning Active FR2849381B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0216872A FR2849381B1 (en) 2002-12-30 2002-12-30 Cosmetic composition, solar and bio-tanning

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
FR0216872A FR2849381B1 (en) 2002-12-30 2002-12-30 Cosmetic composition, solar and bio-tanning
US10/537,816 US20060029563A1 (en) 2002-12-30 2003-12-23 Cutanceous metabolic bio-activator
JP2004564302A JP4249710B2 (en) 2002-12-30 2003-12-23 Skin metabolism physiologically active substance
AU2003303607A AU2003303607A1 (en) 2002-12-30 2003-12-23 Cutaneous metabolic bio-activator
PCT/FR2003/003883 WO2004060393A2 (en) 2002-12-30 2003-12-23 Cutaneous metabolic bio-activator
EP03814486.1A EP1581177B1 (en) 2002-12-30 2003-12-23 Cutaneous metabolic bio-activator
KR1020057012464A KR101007637B1 (en) 2002-12-30 2003-12-23 Cutaneous metabolic bio-activator
ES03814486.1T ES2668072T3 (en) 2002-12-30 2003-12-23 skin metabolic Bioactivator
CA2528101A CA2528101C (en) 2002-12-30 2003-12-23 Cutaneous metabolic bio-activator

Publications (2)

Publication Number Publication Date
FR2849381A1 true FR2849381A1 (en) 2004-07-02
FR2849381B1 FR2849381B1 (en) 2005-02-25

Family

ID=32480298

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0216872A Active FR2849381B1 (en) 2002-12-30 2002-12-30 Cosmetic composition, solar and bio-tanning

Country Status (1)

Country Link
FR (1) FR2849381B1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2904550A1 (en) * 2006-08-03 2008-02-08 Soc Extraction Principes Actif Use of hydrolysed salmon eggs in cosmetic, dermatological and-or pharmaceutical compositions for increasing melanin synthesis in melanocytes of hair or skin, e.g. in suntan creams and hair lotions
WO2014160015A1 (en) * 2013-03-13 2014-10-02 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272079A (en) * 1988-07-06 1993-12-21 Applied Genetics, Inc. Purification and administration of DNA repair enzymes
WO1994014419A1 (en) * 1992-12-21 1994-07-07 Applied Genetics Inc. Tanning method using dna repair liposomes
EP0707844A2 (en) * 1994-10-20 1996-04-24 California Suncare Inc. Liposome delivery of compositions to enhance tanning and repair UV damage
WO1999025819A2 (en) * 1997-11-15 1999-05-27 Aventis Pharma Deutschland Gmbh Antisense oligonucleotides against tenascin for treating vitiligo
WO1999063828A1 (en) * 1998-06-08 1999-12-16 Emory University Broad specificity dna damage endonuclease
WO2002049593A2 (en) * 2000-12-20 2002-06-27 Henkel Kommanditgesellschaft Auf Aktien Use of dna repair enzymes as mmp-1 inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272079A (en) * 1988-07-06 1993-12-21 Applied Genetics, Inc. Purification and administration of DNA repair enzymes
WO1994014419A1 (en) * 1992-12-21 1994-07-07 Applied Genetics Inc. Tanning method using dna repair liposomes
EP0707844A2 (en) * 1994-10-20 1996-04-24 California Suncare Inc. Liposome delivery of compositions to enhance tanning and repair UV damage
WO1999025819A2 (en) * 1997-11-15 1999-05-27 Aventis Pharma Deutschland Gmbh Antisense oligonucleotides against tenascin for treating vitiligo
WO1999063828A1 (en) * 1998-06-08 1999-12-16 Emory University Broad specificity dna damage endonuclease
WO2002049593A2 (en) * 2000-12-20 2002-06-27 Henkel Kommanditgesellschaft Auf Aktien Use of dna repair enzymes as mmp-1 inhibitors

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2904550A1 (en) * 2006-08-03 2008-02-08 Soc Extraction Principes Actif Use of hydrolysed salmon eggs in cosmetic, dermatological and-or pharmaceutical compositions for increasing melanin synthesis in melanocytes of hair or skin, e.g. in suntan creams and hair lotions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
WO2014160015A1 (en) * 2013-03-13 2014-10-02 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9439926B2 (en) 2013-03-13 2016-09-13 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9480642B2 (en) 2013-03-13 2016-11-01 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9498535B2 (en) 2013-03-13 2016-11-22 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9585829B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9585817B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9636291B2 (en) 2013-03-13 2017-05-02 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9682102B2 (en) 2013-03-13 2017-06-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687504B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9694083B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9694029B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9700626B2 (en) 2013-03-13 2017-07-11 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9717680B2 (en) 2013-03-13 2017-08-01 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9757467B2 (en) 2013-03-13 2017-09-12 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9827316B2 (en) 2013-03-13 2017-11-28 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9844506B2 (en) 2013-03-13 2017-12-19 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9872818B2 (en) 2013-03-13 2018-01-23 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9913793B2 (en) 2013-03-13 2018-03-13 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9931370B2 (en) 2013-03-13 2018-04-03 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9937221B2 (en) 2013-03-13 2018-04-10 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9943562B2 (en) 2013-03-13 2018-04-17 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9956290B2 (en) 2013-03-13 2018-05-01 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US10028994B2 (en) 2013-03-13 2018-07-24 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10034828B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US10034944B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US10064955B2 (en) 2013-03-13 2018-09-04 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US10071117B2 (en) 2013-03-13 2018-09-11 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US10080768B2 (en) 2013-03-13 2018-09-25 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US10155048B2 (en) 2013-03-13 2018-12-18 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10188603B2 (en) 2013-03-13 2019-01-29 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US10213457B2 (en) 2013-03-13 2019-02-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10226511B2 (en) 2013-03-13 2019-03-12 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions

Also Published As

Publication number Publication date
FR2849381B1 (en) 2005-02-25

Similar Documents

Publication Publication Date Title
JP3730603B2 (en) Skin external composition for alleviating sagging and dark circles under the eyes
CN1933805B (en) Cosmetic or dermopharmaceutical medicine for reducing wrinkle because of age
JP4572003B2 (en) Natural aging or senescence hyperactive (sunburn, contamination) during use as scarring, or skin chemicals as coercive wetting and peptides cosmetics for skin appearance improvement
JP4256389B2 (en) Composition comprising a mixture of tetrapeptide and tripeptide
EP0755673B1 (en) Stable composition containing a water-sensitive cosmetic and/or dermatalogic agent
CA2185037C (en) Iridaceae extract and compositions containing the same
JP3782779B2 (en) External preparation for skin
CN1094342C (en) Cosmetic preparation with peptide addition
US4839164A (en) Trehalose containing cosmetic composition and method of using it
EP1061895B1 (en) Synergetic composition comprising a compound with lipoaminoacid structure and a tuberous water-lily extract
CA2749750C (en) Skin care compositions and methods of use thereof
EP0761204A1 (en) Use of extracts of filamentous, non photosynthetic bacteria and the composition containing them
KR20030022138A (en) Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
FR2885522A1 (en) Cosmetic or dermopharmaceutical composition containing teprenone
JPH0940545A (en) Ascorbic acid-containing stable composition
FR2557452A1 (en) New compositions for skin care containing evening primrose oil, and tissue features of spleen
JPWO2004075621A1 (en) Anti-aging agent and collagen production promoter
KR20060032594A (en) Modified soy proteins in skin tightening compositions
JP3037145B2 (en) Silicone composition comprising a water-reactive active agent
CA2378644A1 (en) Use of fibres as an anti-irritant agent in a cosmetic or dermatological composition
JP2005501805A (en) Thermus family process for the production of proteins by fermentation of microorganisms, a mixture of proteins obtained in this manner, and cosmetic compositions containing them
CA2528101C (en) Cutaneous metabolic bio-activator
FR2788777A1 (en) New arginine-proline peptides, useful in cosmetics and dermatology for treating e.g. inflammation, inhibit overproduction of proinflammatory interleukins
US9289460B2 (en) Use of natural active substances in cosmetic or therapeutic compositions
JP2004203811A (en) Cosmetic

Legal Events

Date Code Title Description
TP Transmission of property
AU Other act affecting the ownership or exploitation of an industrial property right
CL Concession to grant licences
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16